November 13, 2019

MabPlex Congratulates Encure Biopharma with FDA IND Clearance of YH001 for the Treatment of a Broad Range of Cancers

MabPlex International Ltd. confirms securing United States Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for Encure Biopharma Co., Ltd.’s (Beijing) YH001 project. Following […]
October 10, 2019

MabPlex Lauded by Frost & Sullivan for Global Expansion of ADC Contract Manufacturing Services

Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan has recognized MabPlex International Ltd. (MabPlex) with […]
August 11, 2019

MabPlex International Announces Appointment of Dr. Wei Chen (Ph.D) as Chief Executive Officer

MabPlex International Ltd (MabPlex) has appointed Wei Chen Ph.D as the company’s new Chief Executive Officer (CEO). Dr. Chen, a senior biopharmaceutical professional who has participated […]
January 17, 2019

MabPlex Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration

MabPlex International, Ltd, a global Contract Development and Manufacturing Organization (CDMO ) offering services in the development and manufacturing of biopharmaceuticals, announced that an Investigational New […]